Elicio Therapeutics, Inc.
NASDAQ:ELTXBiotechnology
-$0.89 today
- Market cap
- $51.48M
- Beta
- 1.14
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$2.21
Volume 0.41M
Average 0.34M
ELTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Elicio Therapeutics, Inc.NASDAQ: ELTX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $868K rose 67.9% year over year, behind the +83.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 12.4% from the prior quarter. Over 3 fiscal years it compounded at +67.0% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +67.9% toward the trailing-twelve-month pace of +83.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 2.7M USD
- Year-over-year change
- +85.7%
- 4-year CAGR
- +44.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.7M | +85.7% |
| FY2024 | 2024-12-31 | 1.45M | +23.2% |
| FY2023 | 2023-12-31 | 1.18M | +103.6% |
| FY2022 | 2022-12-31 | 579K | -6.3% |
| FY2021 | 2021-12-31 | 617.76K | — |
Stock-Based Compensation vs competitors
How ELTX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +83.8% is the 2nd highest of 9, against a peer median of -4.9%.
- Over three fiscal years its annual growth of +67.0% compares with a peer median of -0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.03M USD | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $7.62M USD | -49.8% | -20.2% | — | |
| LTM Mar 2026 | $6.67M USD | -45.2% | -9.2% | 210.3% | |
| LTM Mar 2026 | $6.49M USD | -5.6% | +3.2% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $6.28M USD | +111.2% | +109.9% | — |
| LTM Mar 2026 | $6.14M USD | +9.4% | -6.2% | 344.3% | |
| LTM Mar 2026 | $5.99M USD | +19.7% | +10.2% | 1140.6% | |
| LTM Mar 2026 | CHF 4.21M CHF | -4.1% | -4.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.05M USD | +83.8% | +67.0% | — |
| Peer median (excluding ELTX) | — | -4.9% | -0.7% | 344.3% | |
Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.4M) | (28.21M) | (35.2M) | (51.9M) | (39.57M) |
| Depreciation & Amortization | 251.45K | 1.06M | 1.17M | 1.18M | 1.13M |
| Deferred Income Tax | 52.96K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 617.76K | 579K | 1.18M | 1.45M | 2.7M |
| Change in Working Capital | 872.44K | (150K) | (57K) | 3.96M | (3.45M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 30.23K | 1.13M | 23K | (3.33M) | (366K) |
| Other Working Capital | 842.21K | (1.28M) | (80K) | 7.29M | (3.08M) |
| Other Non-Cash Items | 667.05K | 4.54M | 209K | 8.24M | 2.24M |
| Operating Cash Flow | (23.94M) | (22.18M) | (32.69M) | (37.07M) | (36.95M) |
| Capital Expenditures | (525.36K) | (654K) | (66K) | (87K) | (16K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 34K | 3K | 0 |
| Investing Cash Flow | (525.36K) | (654K) | (32K) | (84K) | (16K) |
| Debt Repayment | 14.03M | 0 | 10M | 19.73M | 9.87M |
| Common Stock Issued | 101.38K | 82K | 7M | 5.64M | 26.83M |
| Common Stock Repurchased | 0 | 0 | (150K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 314.88K | 82K | 21.76M | 16.96M | 0 |
| Financing Cash Flow | 19.39M | 21.2M | 38.61M | 42.32M | 36.7M |
| Effect of Forex Changes | 3K | 0 | (68K) | 22K | 40K |
| Net Change in Cash | (5.07M) | (1.63M) | 5.89M | 5.19M | (233K) |
| Free Cash Flow | (24.46M) | (22.83M) | (32.76M) | (37.16M) | (36.97M) |
Elicio Therapeutics, Inc.
NASDAQ:ELTX
Intrinsic Alpha fair value
Locked
Current Price
$2.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.